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Abstract
Background: Influenza pneumonia causes high mortality every year, and pandemic episodes kill millions of people.
Influenza-related mortality has been variously ascribed to an ineffective host response that fails to limit viral replication, an
excessive host inflammatory response that results in lung injury and impairment of gas exchange, or to bacterial
superinfection. We sought to determine whether lung inflammation promoted or impaired host survival in influenza
pneumonia.
Methods and Findings: To distinguish among these possible causes of influenza-related death, we induced robust lung
inflammation by exposing mice to an aerosolized bacterial lysate prior to challenge with live virus. The treatment induced
expression of the inflammatory cytokines IL-6 and TNF in bronchoalveolar lavage fluid 8- and 40-fold greater, respectively,
than that caused by lethal influenza infection. Yet, this augmented inflammation was associated with striking resistance to
host mortality (0% vs 90% survival, p=0.0001) and reduced viral titers (p=0.004). Bacterial superinfection of virus infected
lungs was not observed. When mice were repeatedly exposed to the bacterial lysate, as would be clinically desirable during
an influenza epidemic, there was no tachyphylaxis of the induced viral resistance. When the bacterial lysate was
administered after the viral challenge, there was still some mortality benefit, and when ribavirin was added to the
aerosolized bacterial lysate, host survival was synergistically improved (0% vs 93.3% survival, p,0.0001).
Conclusions: Together, these data indicate that innate immune resistance to influenza can be effectively stimulated, and
suggest that ineffective rather than excessive inflammation is the major cause of mortality in influenza pneumonia.
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Introduction
The annual worldwide mortality associated with pneumonia
exceeds that of any other infection [1,2,3]. In particular, influenza
pneumonia annually causes more than 40,000 deaths in the
United States alone [4,5]. Beyond the impact of seasonal
influenza, episodes of pandemic influenza have accounted for as
many as 50 million deaths [6]. H5N1 avian influenza has already
caused more than 240 human deaths worldwide (http://www.
who.int/csr/disease/avian_influenza/), and increased globaliza-
tion since 1918 suggests that eventual human-to-human transmis-
sion of avian influenza may cause even greater lethality than the
infamous ‘‘Spanish flu’’ [7]. Further, viral pathogens, including
influenza, are considered potential agents of bioterror [8].
The mechanisms underlying influenza-related mortality remain
controversial. Progressive pneumonia following an insufficient
antiviral host response is one possible cause [9]. Virally-induced
excessive and/or dysregulated lung inflammation is another
potential mechanism [10,11,12,13]. Secondary bacterial infections
have also been proposed as the primary contributors to influenza-
related mortality, due to virally-injured epithelium or virus-
attenuated leukocyte responses [13,14,15].
We have recently reported that treatment with an aerosolized
lysate of nontypeable Haemophilus influenzae (NTHi) induces
profound inflammation in the lungs, yet it strongly protects mice
against otherwise fatal bacterial pneumonia [16]. The induced
protective phenomenon, known as Stimulated Innate Resistance
(StIR), is maximal within 4 h of treatment and does not rely on
recruited neutrophils or resident mast cells and alveolar macro-
phages. Given the profound induction of lung inflammation by
this treatment, we perceived an opportunity to determine whether
host inflammation contributed to or prevented mortality in
influenza A pneumonia.
We demonstrate that, despite inducing inflammation greater
than that observed in lethally infected animals, the aerosolized
NTHi lysate results in remarkable protection against otherwise
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4176lethal influenza pneumonia, and that it can be synergistically
combined with antiviral medicine for post-infectious treatment.
Together, these data suggest that ineffective rather than excessive
inflammation is the major cause of mortality in influenza
pneumonia, and indicate that innate immune resistance to viruses
can be therapeutically stimulated to protect populations from
pandemic influenza.
Results
Protection against influenza A pneumonia
Having shown that profound inflammatory lung responses to a
bacterial lysate improved survival of mice infected with non-
cognate bacteria [16], we investigated the effect of stimulation of
lung mucosal innate immunity on survival of influenza A
pneumonia. Mice challenged by aerosol with influenza A/Hong
Kong/8/68 (H3N2) (A/HK) universally succumbed to hemor-
rhagic pneumonia unless pretreated with aerosolized NTHi lysate
(Fig. 1A). This treatment reduced mortality .90% if delivered on
the day prior to infection, .50% if delivered 3 days prior to
infection, and to a lesser degree if delivered one day after infection
(Fig. 1B). Mortality occurred within 10 days of the viral
inoculation, and observation for 21 days after infection showed
no subsequent mortality. The protection imparted by the
aerosolized lysate was paralleled by the recovery of body weight
lost early in the course of infection (Fig. 1C). Lysate-induced
survival was accompanied by a significant reduction in viral load
on the fourth day after challenge (Fig. 1D).
Protection is associated with lung-restricted
inflammation
Since prior reports have described poorer outcomes associated
with virus-induced inflammation [10,11], we compared the
inflammation induced by the NTHi lysate, inflammation induced
by influenza infection, and inflammation induced by the
combination of treatment and infection. Figure 2 shows that
single or repeated treatment with NTHi lysate induces dramatic
inflammation in the lungs, measured by cytokine levels (Fig. 2A)
and cellular influx (Fig. 2D).
Remarkably, while treatment with NTHi lysate acutely induces
8-fold more IL-6 and almost 40-fold more TNF than infection
alone, the treated mice actually have lower levels of inflammatory
cytokines in their lungs by day 3 after the infection (Fig. 2B). By
that time after treatment, the NTHi lysate-induced rise in
cytokines in uninfected mice has entirely resolved (data not
shown), and the inflammatory cell infiltration has fallen by more
than 80%[16]. Together, this suggests that a robust early
inflammatory reaction may allow for more rapid resolution of
the infection-induced inflammation. Notably, the intense inflam-
mation observed in the lungs is not seen systemically. Despite
increases in IL-6 and TNF of 700- and 900-fold in the lungs,
respectively, these cytokines increase only minimally and tran-
siently in the serum (Fig. 2C).
Protection is associated with interferon signaling
Since interferon signaling is essential to baseline host antiviral
resistance in the lungs [17,18], we investigated whether treatment
with NTHi lysate was capable of inducing an interferon response.
In addition to the robust induction of inflammatory cytokines, we
found that NTHi lysate treatment also induces significant increases
in lung interferon c levels (Fig. 2A). However, unlike IL-6 and
TNF, the fulminant influenza infections observed in untreated
mice actually induce 4-fold higher levels of interferon c than the
NTHi lysate treatment (Fig. 2B). Presumably this reflects the
ongoing antiviral response of the host, in contrast to the better
contained infections of the treated mice.
To further characterize the lung interferon response to the
NTHi lysate, we assessed gene expression using whole genome
microarray analysis. As maximal resistance against S. pneumoniae is
achieved by 4 h post-treatment, we compared gene expression of
Figure 1. Aerosolized NTHi lysate protects against hemorrhagic influenza virus pneumonia. (A) Gross pathologic images of lungs 7 days
after influenza A challenge. (B) Mice were challenged with aerosolized influenza A (2.8610
4 TCID50/ml) after receiving no NTHi lysate treatment, or
NTHi lysate treatment 3 days before, 1 day before, or 1 day after infection (* p=0.0001, { p=0.011, { p=0.043 when each treated group was
compared to the untreated group). (C) Weight changes in the same groups of mice shown in A.( D) Viral titers in lung homogenates were measured
4 days after viral challenge, with or without a single NTHi lysate pretreatment 1 day prior to infection (* p=0.004).
doi:10.1371/journal.pone.0004176.g001
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treatment. Pathway analysis revealed interferon signaling to be
among the most upregulated events following NTHi lysate
treatment (p,10
211). Interferon signaling pathway transcripts
are reported in Table 1, showing that treatment induces
expression of numerous transcripts critical for both type I
(interferon-a/b) and type II (interferon-c) signaling.
Prolonged protection without tachyphylaxis following
repetitive dosing
Since a high level of protection against influenza virus only lasts
for 3 days (Fig. 1), prolonged protection would require repetitive
dosing. To test whether tachyphylaxis to the protective effects of
the aerosolized NTHi lysate occurs, we challenged mice with
influenza in three different conditions: no lysate treatment, a single
lysate treatment, or repetitive lysate treatment. We again observed
100% mortality in the untreated group, but found identical
protection by NTHi lysate treatment whether given once one day
prior to infection, or given three times (seven, four and one days
prior to infection, Fig. 3A). In both NTHi lysate treated groups,
protection was associated with recovery of early weight loss by the
fifth day after infection (Fig. 3B). Observation for 21 days after the
challenge showed no subsequent mortality.
Treatment with a combination of aerosolized NTHi lysate
and ribavirin after infection
An alternative to repetitive stimulation of lung innate immunity
for prophylaxis during an epidemic viral infection would be to
treat with the pro-inflammatory aerosol after infection in
combination with an antiviral drug. We recently found that
Figure 2. Protection against influenza A is associated with lung-restricted inflammation. (A) Lung inflammatory cytokine levels were
determined in mice treated with NTHi lysate once (‘‘61’’), every third day for 6 days (‘‘63’’), or not at all. ELISA was performed on BAL fluid obtained
4 h after the final treatment. (B) Lung inflammatory cytokines were measured 3 days after influenza A infection without NTHi lysate pretreatment,
following a single treatment on day 21 before infection, or following treatments on days 27, 24, and 21 prior to infection. (C) Serum levels of
inflammatory cytokines at designated timepoints after NTHi lysate treatment. (D) Inflammatory cell counts in BAL fluid of mice treated (or not) with
NTHi lysate, as in A. (E) Inflammatory cell counts in BAL fluid of mice treated (or not) with NTHi lysate then infected with influenza A, as in B. (*p,0.01
compared with untreated).
doi:10.1371/journal.pone.0004176.g002
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Symbol Definition 2 h fold change 4 h fold change Accession
G1p2 Interferon alpha-inducible protein 4.51 8.00 NM_015783.1
Icsbp1 Interferon consensus sequence binding protein 1 1.20 1.07 NM_008320.2
Ifi1 Interferon inducible protein 1 3.68 2.38 NM_008326.1
Ifi16 Interferon gamma-inducible protein 16 1.22 2.24 NM_008329.1
Ifi202b Interferon activated gene 202B 2.48 ND NM_008327.1
Ifi203 Interferon activated gene 203 1.44 2.40 NM_008328.1
Ifi205 Interferon activated gene 205 24.22 53.00 NM_172648.2
Ifi30 Interferon gamma inducible protein 30 1.044 0.72 NM_023065.2
Ifi35 Interferon-induced protein 35 1.20 1.34 NM_027320.1
Ifi47 Interferon gamma inducible protein 4.66 3.60 NM_008330.1
Ifit1 Interferon-induced protein with tetratricopeptide repeats 1 ND ND NM_008331
Ifit2 Interferon-induced protein with tetratricopeptide repeats 2 2.01 4.23 NM_008332.2
Ifit3 Interferon-induced protein with tetratricopeptide repeats 3 3.08 4.21 NM_010501.1
Ifitm1 Interferon-induced transmembrane protein 1 2.66 2.59 NM_026820.2
Ifitm2 Interferon-induced transmembrane protein 2 1.75 1.36 NM_030694
Ifitm3 Interferon-induced transmembrane protein 3 1.70 1.34 NM_025378.1
Ifitm5 Interferon-induced induced transmembrane protein 5 1.53 2.40 NM_053088
Ifitm7 Interferon-induced transmembrane protein 7 0.70 0.72 NM_028968
Ifna1 Interferon alpha family gene 1 1.74 1.69 NM_010502.1
Ifna2 Interferon alpha family gene 2 ND ND NM_010503.1
Ifna4 Interferon alpha family gene 4 ND ND NM_010504.1
Ifna5 Interferon alpha family gene 5 0.93 0.81 NM_010505
Ifna6 Interferon alpha family gene 6 ND 9.08 NM_008335.1
Ifna7 Interferon alpha family gene 7 1.50 0.55 NM_008334
Ifna9 Interferon alpha family gene 9 ND ND NM_010507.1
Ifna11 Interferon alpha family gene 11 1.05 0.94 NM_008333
Ifna12 Interferon alpha family gene 12 ND ND NM_177361.2
Ifna13 Interferon alpha family gene 13 ND ND NM_177347.2
Ifnar1 Interferon (alpha and beta) receptor 1 1.87 4.84 NM_010508.1
Ifnar2 Interferon (alpha and beta) receptor 2 2.63 1.87 NM_010509.1
Ifng Interferon gamma ND 8.63 NM_008337.1
Ifngr1 Interferon gamma receptor 1 1.03 0.69 NM_010511.1
Ifngr2 Interferon gamma receptor 2 4.67 2.96 NM_008338.2
Ifrd1 Interferon-related developmental regulator 1 7.09 11.35 NM_013562
Ifrd2 Interferon-related developmental regulator 2 0.85 1.05 NM_025903.1
Ifrg15 Interferon alpha responsive gene 1.158 1.34 NM_022329.2
Igtp Interferon gamma induced GTPase 1.92 2.57 NM_018738.2
Irebf1 Interferon response element binding factor 1 ND 9.45 NM_013714.1
Irf1 Interferon regulatory factor 1 5.43 1.96 NM_008390.1
Irf2 Interferon regulatory factor 2 1.01 0.93 NM_008391.2
Irf2bp1 Interferon regulatory factor 2 binding protein 1 0.68 0.82 NM_178757.3
Irf3 Interferon regulatory factor 3 1.24 0.93 NM_016849.2
Irf4 Interferon regulatory factor 4 2.63 1.73 NM_013674.1
Irf5 Interferon regulatory factor 5 1.81 1.57 NM_012057.1
Irf6 Interferon regulatory factor 6 1.11 1.02 NM_016851.1
Irf7 Interferon regulatory factor 7 1.60 3.18 NM_016850.1
Isg20 Interferon-stimulated protein 1.90 1.69 NM_020583.4
Isgf3g Interferon dependent positive acting transcription factor 3 gamma. 2.27 1.24 NM_008394.2
Jak1 Janus kinase 1 1.30 1.25 NM_146145.1
Jak2 Janus kinase 2 2.26 1.44 NM_008413.1
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influenza virus provided some survival improvement in mice [19].
To test whether these two interventions might be effectively
combined, mice were infected with influenza virus then treated
with ribavirin alone, NTHi lysate alone, or a combination of the
two. Ribavirin alone did not improve survival with the high level
infectious challenge used in this study. However, as shown in
Figure 4, suspending ribavirin in a single dose of NTHi lysate on
day 1 after infection improved survival significantly more than
NTHi lysate alone (66.7% vs 20.0% survival, p=0.013), and an
additional NTHi lysate treatment on day 2 almost completely
protected from mortality (93.3% survival, p,0.0001 vs. control).
No untoward effects or additional protection were noted if a third
NTHi lysate dose was added on day 3. Observations through day
21 showed no subsequent mortality.
Discussion
Lower respiratory tract infections are the leading cause of
infectious death worldwide[1]. We have recently shown that
Stimulated Innate Resistance (StIR) of the lungs induced by an
aerosolized bacterial lysate can protect mice against otherwise fatal
bacterial pneumonias [16]. We show here that the same treatment
can prevent viral pneumonia, despite induction of lung inflam-
Symbol Definition 2 h fold change 4 h fold change Accession
Mx1 Myxovirus (influenza virus) resistance 1 8.02 16.69 NM_010846
Oas1g 2–5 oligoadenylate synthetase 1G 2.47 3.00 NM_011852.2
Prkr Protein kinase interferon-inducible double stranded RNA dependent 1.69 2.63 NM_011163.2
Prkrir Protein kinase interferon-inducible double stranded RNA dependent inhibitor
repressor of (P58 repressor)
1.17 0.94 NM_028410.1
Psmb8 Proteosome (prosome macropain) subunit beta type 8 (large multifunctional
protease 7)
1.41 1.54 NM_010724
Ptpn2 Protein tyrosine phosphatase non-receptor type 2 18.90 6.05 AK076072
Socs1 Suppressor of cytokine signaling 1 1.63 1.16 NM_009896
Stat1 Signal transducer and activator of transcription 1 1.34 1.25 NM_009283.2
Stat2 Signal transducer and activator of transcription 2 3.27 3.24 NM_019963.1
Tap1 Transporter 1 ATP-binding cassette sub-family B (MDR/TAP) 1.59 2.85 NM_013683.1
Tyk2 Tyrosine kinase 2 1.22 0.97 NM_018793.1
Fold change, lung interferon gene expression 2 or 4 h after NTHi lysate treatment, compared to untreated mice. Accession, GenBank accession number. ND, no gene
expression detected at the designated time point.
doi:10.1371/journal.pone.0004176.t001
Table 1. cont.
Figure 3. Repeated doses of aerosolized NTHi lysate provide prolonged protection against influenza virus without tachyphylaxis.
(A) Mice were challenged with aerosolized influenza A without NTHi lysate pretreatment, following a single treatment on day 21 before infection, or
following treatments on days 27, 24, and 21 prior to infection. Survival curves are shown (*p,0.0001). (B) Weight changes in the same groups of
mice shown in A.
doi:10.1371/journal.pone.0004176.g003
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infection.
Influenza-induced excessive and/or dysregulated lung inflam-
mation has been recently described as a mechanism by which
pandemic infections cause mortality [10,11,12,13]. Consequent to
these observations, considerable effort has been invested in
attempts to improve outcomes of influenza-infected mice through
genetic and pharmacologic suppression of inflammatory cytokine
production [12,20,21,22]. In contrast, our current and previous
data demonstrate robust inflammation associated with the
induction of protective host responses (Fig. 3a–d). As we have
previously shown that repetitive treatments result in diminishing
inflammatory responses without loss of protection, it is possible
that the cytokines themselves are not responsible for the protective
effect. However, like our previous observations with protection
against bacterial pathogens [16], the pro-inflammatory pretreat-
ment resulted in a significant reduction in pathogen burden, here
represented by decreased viral titers (Fig. 1d). As interferon
signaling is associated with survival of viral and bacterial
infections, the observation of augmented type I and II interferon
signaling after NTHi lysate treatment (Figure 3A–B, Table 1)
supports our hypothesis that this is also an important element of
anti-viral StIR, and we will explore this in the future.
One manner in which the host response to NTHi lysate differs
from reported pandemic virus-induced inflammation [11] is in its
restriction to the lung. While documenting massive increases in
indicators of lung inflammation following treatment, there is
virtually no systemic inflammation noted (Fig 3c). Similarly,
treatment with NTHi lysate induces no systemic leukocytosis (data
not shown), despite the profound cellular infiltration induced in
the lungs. We presume this confinement of the response to the
lungs explains the lack of morbidity we have observed when mice
are treated acutely even with very high doses of NTHi lysate [16].
Based on these observations, we conclude that influenza
pneumonia does not kill via excessive pulmonary inflammation,
but progresses through a deficit of effective inflammation.
In addition to exuberant lung inflammation, secondary bacterial
infections are often considered important contributors to influen-
za-related mortality [13,14,15]. Interestingly, we here demonstrate
that the host response to bacterial products actually enhances the
clearance of a viral pathogen (Fig. 1D), just as we have shown for
bacteria[16]. So, while viral infections may impair antibacterial
interferon-c responses [15], we observe no evidence that the
response to the bacterial lysate impedes either type I or type II
interferon signaling. Rather, the response to the bacterial products
seems to reinforce protective antiviral events via vigorous
interferon gene expression.
Epidemic respiratory infections, as previously observed with
influenza [10,11] and SARS [23], result in high mortality,
sometimes before the pathogen is identified, and often without
effective post-exposure treatment options. Seasonal influenza,
though the case-mortality rate is lower, still kills ten of thousands of
Americans annually [4,5] and clinicians are faced with the
problems of ineffective vaccine strategies and declining effective-
ness of neuraminidase inhibitors [24,25]. In such situations,
rapidly dispersed, broad protection would be highly advantageous.
At present, the primary means to contain the spread of
influenza and to prevent exposed individuals from developing
disease is through the use of the trivalent hemagglutinin subunit
vaccine or the live-attenuated trivalent vaccine coordinated by the
United Stated Centers for Disease Control and Prevention. This
strategy is limited by the fact that prevalent (potentially pandemic)
strains may not be accurately predicted for inclusion in the annual
vaccine, that normal adaptive immunity is required for protection
against included strains, and that development of immunity takes
weeks – potentially obviating the benefit in the setting of a rapidly
spreading outbreak.
In this study, we showed that a single treatment with NTHi
lysate was sufficient to prevent otherwise fatal influenza pneumo-
nia (Fig. 1). The aerosolized lysate was also administered
repetitively to model the sustained protection that would be
clinically desirable during an influenza epidemic. No tachyphy-
laxis to the influenza-protective effect was observed with successive
administrations (Fig. 2), despite the fact that the rise in lung lavage
neutrophils induced by the aerosolized lysate becomes less with
repeated administration [26]. These findings are consistent with
the development of tolerance to the inflammatory effects of innate
immune stimulation without loss of antimicrobial effector function,
as recently described [27]. Alternatively, the progressive reduction
in inflammation could reflect the tempering of innate immune
responses by adaptive immune cells that become engaged with
repetitive stimulation [28].
In addition to the preventive benefits of NTHi lysate-induced
StIR, we show that stimulation of lung innate immunity can be
therapeutically combined with an antiviral medication after
influenza infection to improve survival more than either treatment
alone (Fig. 4). In our current and prior work, we have reported
only a modest survival benefit when the lysate is delivered 24 h
Figure 4. Aerosolized NTHi lysate combined with ribavirin effectively treats influenza virus pneumonia. After aerosolized challenge
with ,10
7 TCID50/mouse influenza A, mice were treated with high dose ribavirin (Rib), NTHi lysate, or a combination of the two. Combination treated
mice received ribavirin+NTHi therapy for the days indicated, up to three days. (A) Survival at day 14 for each of the conditions (*p,0.0001,
{p=0.0002, {p0.2 compared with untreated). (B) Survival curves for each of the conditions in A.
doi:10.1371/journal.pone.0004176.g004
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antimicrobial inflammatory lung environment for up to 72 h
potentiates the effects of high dose ribavirin and almost completely
averts an otherwise uniformly fatal outcome. While Zheng and
colleagues [22] recently reported improved influenza survival from
0% to 53.3% with the anti-viral/anti-inflammatory combination
of zanamivir, celecoxib and mesalazine, we believe our current
study to be the first to demonstrate such dramatic protection
(improved from 0% to 93.3% survival) with an anti-viral
combination known to induce inflammation. The seeming
contradiction of these results may best be resolved by the
hypothesis that the anti-inflammatory regimen diminished some
toxicity associated with uncontrolled immune responses (i.e.,
reduced harmful inflammation) while our pro-inflammatory
combination promoted the robust generation of defense effectors
(i.e., enhanced protective inflammation).
In summary, we have shown that stimulation of lung mucosal
innate immunity with a complex bacterial lysate confers striking
protection against a virulent viral pathogen. Resistance to
influenza is stimulated despite profound induction of lung-
restricted inflammation, suggesting that excessive pulmonary
inflammation is not the primary cause of influenza-induced
mortality. Further, we found that the same treatment can be
combined in the post-exposure setting with antiviral medication to
improve survival. Taken together, we infer that therapeutic
manipulation of StIR may be possible to reduce the mortality
burden associated with viral pneumonias, and potentially, to
protect the population against bioterror attacks.
Methods
Animals
Six to eight week old NIH Swiss-Webster mice (Charles River)
were used for viral challenges. For protection studies, mice were
divided into groups of 20 mice (5 for virus lung titers, 15 for
survival). For bronchoalveolar lavage assays, an additional 5 mice
were added for each group. Six to eight week old C57BL/6 mice
were used for gene expression analysis, 6 mice per condition. Mice
were handled in accordance with protocols approved by the
Institutional Animal Care and Use Committees of Baylor College
of Medicine and The University of Texas-M.D. Anderson Cancer
Center, and euthanized if distressed.
Bacterial lysate aerosol treatment
Non-typeable Haemophilus influenzae (NTHi) was stored, grown
and harvested as described [16,26]. The cell pellet was washed
and resuspended in 20 ml 0.9% sodium chloride solution. This
suspension was passed three times through an EmulsiFlex C5
cell disruptor (Avestin) at greater then 10,000 psi, then diluted
to 4–5 mg/ml in 0.9% sodium chloride solution by bicincho-
ninic assay (Pierce) and centrifuged at 15,0006g for 10 min.
The supernatant was collected, the protein concentration was
adjusted to 2.5 mg/ml, and the lysate was sterilized by passage
through a 0.2 mm filter and frozen in 8 ml aliquots at 280uC.
Treatment of mice with aerosolized lysate was performed as
described [16], delivering 8 mL of suspension during each
30 min exposure.
Influenza A challenge
A clinical isolate of influenza A/Hong Kong/8/68 (H3N2) (A/
HK; Mouse Lung Pool 11-29-05) virus that had been passaged at
least nine times through mice was stored as frozen stock (2.8610
7
TCID50/ml) in the supernatant of mouse lung homogenates [29].
Stock was diluted 1:300–1:1,000 in 0.05% gelatin in Eagle’s
minimal essential medium (Sigma-Aldrich) and aerosolized for
20 min to achieve LD90–LD100 (target 100 TDIC50/mouse). Viral
concentration in the nebulizer before and after aerosolization and
in lung homogenates was determined by hemagglutination assay of
infected MDCK cells [30]. In some experiments, 1 g of ribavirin
was dissolved in 10 ml of NTHi lysate prior to aerosolization.
Final ribavirin and lysate protein concentrations were 100 mg/ml
and 2.5 mg/ml, respectively. Mice were challenged without
pretreatment, following pretreatment on day 21, or following
pretreatment on days 27, 24 and 21. On day 0, all groups of
mice were exposed to the same viral aerosol. On day +4, 5 mice
from each group were sacrificed and their lungs removed. Lungs
were homogenized by beadbeating and the levels of virus
determined. Remaining mice in each group were observed daily
for up to 21 days for overt illness, morbidity and mortality. Mice
were weighed on days 0 and +4, and three times weekly from day
+7 until day +21.
Host response to pathogen challenge
To characterize the inflammatory host response to treatment
and/or infection lung lavage and cell counts were performed as
described [16]. In order to assess the response to NTHi lysate
treatment, lavage samples from unchallenged mice were obtained
4 h after the final (or only) NTHi lysate treatment. In order to
collect samples during acute virus-induced illness, lavage samples
were also collected on day +3 following infection with influenza.
Multiplex ELISA cytokine analysis was performed by Searchlight
Protein Array Analysis (Pierce Biotechnology). Total leukocyte
count was determined with a hemacytometer, and differential
count by cytocentrifugation of 300 ml of bronchoalveolar lavage
fluid at 4506g for 5 min, followed by Wright-Giemsa staining.
Gene expression analysis
To better understand the gene expression response to the
treatment, mice were treated with the aerosolized NTHi lysate,
then euthanized after 2 h or 4 h for comparison to untreated mice.
To reduce the lung leukocyte burden, the pulmonary vasculature
was perfused and the airways lavaged with PBS. The lungs were
mechanically homogenized, then total RNA was isolated from
lung homogenates using the RNeasy system (Qiagen), and cRNA
was synthesized and amplified from equal masses of total RNA
using the Ilumina TotalPrep RNA amplification kit (Ambion).
Amplified cRNA was hybridized and labeled on Sentrix Mouse-6
Expression BeadChips (Illumina), then scanned on a BeadStation
500 (Illumina). Primary microarray data were deposited at the
NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) consistent with MIAME standards (GEO Accession
GSE13740). Primary signal intensity was normalized between
and within samples, and differentially expressed genes were
identified based on signal change and inter-sample variation.
Gene ontology analysis was performed using the NIAID Database
for Annotation, Visualization and Integrated Discovery (DAVID)
and the KEGG Database (GenomeNet). Differentially expressed
genes were mapped to signaling pathways using Ingenuity
Pathways Analysis 5.0 (Ingenuity Systems), and the pathway
nodules were individually reviewed. C57BL/6 mice were used for
the gene expression studies as they demonstrate similar NTHi
lysate induced protection against all investigated pathogens, and
because the genetically manipulated mice the authors plan to use
to dissect the mechanisms of StIR are primarily on C57BL/6
backgrounds.
To characterize the interferon-related gene expression changes
induced by NTHi, Table 1 presents a list of genes containing all
transcripts from the Ingenuity Pathway Analysis canonical
Lung Inflammation in Influenza
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STAT transcripts in KEGG, and additional interferon related
transcripts identified by the authors. Baseline signal intensity
values of 1 were assigned to undetected control transcripts in order
to avoid reporting infinite fold change values.
Statistical methods
Summary statistics for virus in lung tissue were compared using
Student’s t-test. Proportions of mice surviving pathogen challenges
were compared using Fisher’s exact text, and log-rank compar-
isons of survival distribution were performed using Kaplan-Meier
estimation. All data shown are representative of at least two
independent experiments, and were not combined for analysis
because of modest differences in virus challenge doses. Analyses
were performed using SAS/STAT (SAS Institute).
For gene expression analyses, treated and untreated samples
were compared to identify treatment-induced gene expression
using an ANOVA-based scheme written in R (Free Software
Foundation, Boston, MA), utilizing an Illumina library developed
by Simon Lin, Northwestern University, Chicago, IL.
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